Strategic Family Wealth Counselors L.L.C. Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Strategic Family Wealth Counselors L.L.C. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.8% in the 4th quarter, HoldingsChannel reports. The firm owned 3,497 shares of the company’s stock after acquiring an additional 450 shares during the quarter. Strategic Family Wealth Counselors L.L.C.’s holdings in Johnson & Johnson were worth $506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Callan Family Office LLC raised its holdings in shares of Johnson & Johnson by 269.2% during the fourth quarter. Callan Family Office LLC now owns 36,114 shares of the company’s stock worth $5,223,000 after purchasing an additional 26,331 shares during the last quarter. EagleClaw Capital Managment LLC raised its holdings in shares of Johnson & Johnson by 8.3% during the fourth quarter. EagleClaw Capital Managment LLC now owns 19,896 shares of the company’s stock worth $2,877,000 after purchasing an additional 1,530 shares during the last quarter. E Fund Management Co. Ltd. grew its position in Johnson & Johnson by 65.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 28,376 shares of the company’s stock valued at $4,104,000 after buying an additional 11,181 shares during the period. Candriam S.C.A. grew its position in Johnson & Johnson by 4.5% during the fourth quarter. Candriam S.C.A. now owns 277,054 shares of the company’s stock valued at $40,068,000 after buying an additional 11,902 shares during the period. Finally, Vestmark Advisory Solutions Inc. grew its position in Johnson & Johnson by 55.4% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 33,335 shares of the company’s stock valued at $4,821,000 after buying an additional 11,887 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ? increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $166.81 on Friday. The company’s 50-day moving average price is $152.95 and its 200-day moving average price is $156.30. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $401.61 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.